Relapsed/refractory B-cell lymphoma
Conditions
Interventions
Treatment of relapsed/refractory B-cell lymphoma group with Ogatizumab:Inotuzumab Ozogamicin therapy
Sponsors
Tianjin First Central Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1) Patients with R/R aggressive B-cell lymphoma undergoing third-line or above treatment or their legal guardians sign informed consent for treatment. 2) Male or female patients aged 18-80 years old (including 18 and 80 years old). 3) R/R aggressive B-cell lymphoma was confirmed by pathology, histology and flow cytometry. (1) Liver function: ALT/AST<3 times the upper limit of normal (ULN) and bilirubin =34.2µmol/L; (2) Renal function: creatinine <100µmol/L; (3) Lung function: indoor oxygen saturation =95%; (4) Cardiac function: left ventricular ejection fraction (LVEF) =40%. 5) The patient's peripheral venous blood flow is smooth, which can meet the needs of intravenous infusion. 6) The patient's Karnofsky score was =60.
Exclusion criteria
Exclusion criteria: 1) Women who are pregnant (urine/blood pregnancy test positive) or breastfeeding. 2) Have an infectious disease that cannot be controlled. 3) HIV-infected patients. 4) Pathologically diagnosed with primary tumors other than R/R aggressive B-cell lymphoma. 5) Suffering from serious autoimmune diseases or immunodeficiency diseases. 6) According to the investigators' judgment, the patient has other inappropriate conditions.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PFS of 6 month and 12 month; | — |
Secondary
| Measure | Time frame |
|---|---|
| objective remission rate;complete remission rate;duration of response of one year;overall survival of one year;event free survival of one year; | — |
Countries
China
Contacts
Public ContactDeng Qi
Tianjin First Central Hospital
Outcome results
None listed